Earnings call transcript: Medartis lifts 2026 outlook after strong H1 growth

Medartis reported H1 2026 revenue of CHF 160.8m (+30.7% YoY; +17% organic) with core EBITDA rising to CHF 28.8m and core net profit turning positive at CHF 7m (vs. a CHF 0.4m loss prior year). The company raised full-year 2026 organic sales guidance to 17%–19% and increased its U.S. KeriMedical TOUCH case target to 1,800 from 1,200, while highlighting an 18% core EBITDA margin (up 20bps reported / 90bps currency-adjusted). Despite negative H1 free cash flow of CHF 10m due to heavy capex (CHF 18m in H1; ~CHF 35m expected for FY26), shares rose 2.73% to $90.3, reflecting improved growth momentum and profitability outlook.

Analysis

Medartis is a useful read-through for the orthopedic implant niche: premium, surgeon-education-led products can still take share even in a tough procurement environment, but only if the commercial machine is local and the hospital-contract friction is managed. That tends to favor scaled, direct-selling device platforms with installed training infrastructure and penalizes distributors or smaller competitors relying on third-party channels. The second-order winner is not just the implant maker but any company that can monetize adjacent instrument sets and service relationships; the loser is legacy channel economics if single-use/disposable workflows keep creeping into orthopedic trays.

The near-term risk is that investors extrapolate launch velocity too aggressively. The real catalyst path is over the next 1-3 quarters: conversion from trained surgeons to reimbursed cases, especially in the U.S., and whether the seasonal slowdown or hospital approvals create a visible air pocket in reported growth. Over 6-18 months, the key question is cash conversion—capex is still suppressing FCF, so if gross margin gains and tariff localization do not translate into better cash generation by 2027, the multiple should compress.

Contrarian view: the market may be underweighting the option value of cross-sell once a surgeon is onboarded, but it may also be overpaying for what is still partly a launch story with acquisition/FX tailwinds. Until the company proves that case volume can stay ahead of the training curve and that operating leverage survives the capex cycle, this is more a quality growth compounder than a straight-line growth breakout. That makes the setup attractive on pullbacks, less so after a gap higher near range highs.

Key Decisions for Investors

• No immediate trade in GAP/SO/SYBT/TGT/TSTS; the article has no direct fundamental transmission to the listed names.
• Watch SYK vs ZBH as the cleaner orthopedics pair: long SYK / short ZBH into the next 1-2 earnings cycles if U.S. surgeon conversion remains strong, because direct selling and premium implant mix should outperform a more turnaround-heavy peer.
• Use IHI as the broad medtech proxy on 3-5% pullbacks, with a 6-12 month horizon; risk/reward improves if the market starts rewarding margin expansion over top-line noise.
• Set an alert on medtech/orthopedics names if U.S. case growth slows after the next hospital-contract conversion window; that would falsify the launch-execution thesis and argue for taking profits on any long exposure.